Reuters logo
BRIEF-VTV Therapeutics announces positive topline results from Phase 2 study
December 14, 2016 / 10:07 PM / 9 months ago

BRIEF-VTV Therapeutics announces positive topline results from Phase 2 study

Dec 14 (Reuters) - Vtv Therapeutics Inc :

* Says compound was well-tolerated, with negligible incidences of nausea and vomiting across all arms of study

* Says trends towards weight loss were also observed in the study

* Says analyses of full study results of ttp273 will continue

* Vtv therapeutics announces positive topline results from phase 2 study of ttp273 in type 2 diabetes

* Says ttp273 demonstrated a statistically significant reduction in hba1c

* Vtv Therapeutics Inc - based on these results, co will continue to advance development of ttp273 and enter into discussions with potential partners

* Says the oral small molecule glp-1 receptor agonist met primary endpoint Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below